Trandate: Advanced Blood Pressure Control with Dual-Action Efficacy
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.90 | $57.02 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $114.04 $86.03 (25%) | 🛒 Add to cart |
| 90 | $1.28 | $171.05 $115.04 (33%) | 🛒 Add to cart |
| 120 | $1.20 | $228.07 $144.05 (37%) | 🛒 Add to cart |
| 180 | $1.12 | $342.11 $201.06 (41%) | 🛒 Add to cart |
| 270 | $1.07
Best per pill | $513.16 $289.09 (44%) | 🛒 Add to cart |
Synonyms | |||
Trandate (labetalol hydrochloride) is a prescription antihypertensive medication combining selective alpha-1 and non-selective beta-adrenergic receptor blocking actions. This dual mechanism provides comprehensive blood pressure management by reducing peripheral vascular resistance while maintaining cardiac output. Clinically indicated for hypertension management—including severe cases and hypertensive emergencies—Trandate offers rapid yet controlled blood pressure reduction with established cardiovascular safety profiles. Its unique pharmacodynamic properties make it particularly valuable in clinical scenarios requiring balanced hemodynamic control without compromising end-organ perfusion.
Features
- Contains labetalol hydrochloride as active pharmaceutical ingredient
- Dual alpha- and beta-adrenergic blocking activity (approximately 1:3 ratio)
- Available in tablet formulations (100 mg, 200 mg, 300 mg) and intravenous solution
- Rapid onset of action with peak plasma concentrations within 1-2 hours post-oral administration
- Extensive hepatic metabolism with urinary excretion of metabolites
- Demonstrated efficacy across diverse patient demographics including geriatric populations
Benefits
- Provides simultaneous reduction of peripheral vascular resistance and attenuation of reflex tachycardia
- Maintains cerebral, renal, and coronary blood flow during antihypertensive therapy
- Suitable for long-term hypertension management and acute blood pressure control
- Demonstrates favorable safety profile in patients with reactive airway disease (relative to non-selective beta-blockers)
- Offers flexible dosing regimens adaptable to individual patient response
- Reduces left ventricular workload while preserving cardiac output
Common use
Trandate is primarily indicated for the management of hypertension, both as monotherapy and in combination with other antihypertensive agents. It is particularly effective in treating hypertensive emergencies when administered intravenously, providing controlled blood pressure reduction within 5-10 minutes of administration. The medication finds additional application in managing hypertension during pregnancy (under specialist supervision), perioperative hypertension, and cases where traditional beta-blockers are contraindicated due to bronchospastic conditions. Clinical studies have demonstrated its efficacy in reducing both systolic and diastolic blood pressure across various patient populations, including those with concomitant angina pectoris.
Dosage and direction
Oral Administration: Initiate with 100 mg twice daily, gradually increasing at 2-3 day intervals based on therapeutic response. Maintenance doses typically range from 200-400 mg twice daily, with maximum recommended daily dose of 2400 mg divided into two or three doses. Elderly patients may require lower initial doses (50 mg twice daily).
Intravenous Administration: For hypertensive emergencies, administer 20 mg IV push over 2 minutes. Additional doses of 40-80 mg may be given at 10-minute intervals until target blood pressure achieved, to a maximum total dose of 300 mg. Continuous infusion may be initiated at 2 mg/min, titrated to response.
Administer with or without food, though consistent administration relative to meals is recommended. Tablets should be swallowed whole without crushing or chewing. Regular blood pressure monitoring is essential during dosage titration.
Precautions
- Monitor hepatic function periodically due to extensive hepatic metabolism
- Exercise caution in patients with history of heart failure; may precipitate cardiac decompensation
- Use carefully in diabetic patients as beta-blockade may mask hypoglycemic symptoms
- Orthostatic hypotension may occur, particularly during initial therapy or dosage increases
- Gradual withdrawal is recommended (over 1-2 weeks) to avoid rebound hypertension
- Not recommended for pheochromocytoma without concomitant alpha-blockade
- Monitor pulmonary function in patients with pre-existing respiratory conditions
- May potentiate hypothermia during prolonged exposure to cold environments
Contraindications
- Bronchial asthma or history of bronchospasm
- Overt cardiac failure requiring inotropic support
- Cardiogenic shock
- Severe bradycardia (heart rate <50 bpm)
- Second- or third-degree heart block without functioning pacemaker
- Severe hepatic impairment (Child-Pugh Class C)
- Hypersensitivity to labetalol or any component of the formulation
- Concurrent administration with catecholamine-depleting drugs (e.g., reserpine)
Possible side effect
Common (≥1%):
- Fatigue and dizziness (15-20%)
- Nausea and dyspepsia (5-10%)
- Orthostatic hypotension (3-7%)
- Scalp tingling or numbness (1-5%)
- Ejaculation failure (1-5%)
Less common (<1%):
- Bronchospasm in susceptible individuals
- Heart failure exacerbation
- Hepatotoxicity (elevated transaminases)
- Lupus-like syndrome
- Psoriasis exacerbation
- Depression or sleep disturbances
Rare (<0.1%):
- Severe bradycardia
- Heart block
- Hypersensitivity reactions
- Peyronie’s disease
- Reversible alopecia
Drug interaction
- Calcium channel blockers: Enhanced hypotensive effect and potential for bradycardia
- Digoxin: Additive effects on AV conduction
- Insulin/oral hypoglycemics: Masked hypoglycemic symptoms and potential altered glucose metabolism
- Cimetidine: Increased labetalol plasma concentrations
- Nitroglycerin: Exaggerated hypotension
- Clonidine: Rebound hypertension upon withdrawal
- MAO inhibitors: Potentiated hypertensive crisis
- NSAIDs: Reduced antihypertensive efficacy
- Sympathomimetics: Mutual antagonism of effects
Missed dose
If a dose is missed, administer as soon as remembered unless within 4 hours of the next scheduled dose. Do not double the subsequent dose to compensate for the missed administration. Maintain regular dosing schedule thereafter. Patients should be advised to maintain a consistent dosing routine and use reminder systems if necessary. Extended missed doses may require medical supervision for dose re-titration.
Overdose
Symptoms: Profound hypotension, bradycardia, bronchospasm, cardiac failure, and seizures. Hypoglycemia may occur particularly in diabetic patients.
Management:
- Administer IV fluids for hypotension
- Atropine (0.5-1.0 mg IV) for bradycardia
- Glucagon (1-10 mg IV) to reverse beta-blockade effects
- Vasopressors (norepinephrine or epinephrine) for refractory hypotension
- Cardiac pacing for complete heart block
- Bronchodilators for bronchospasm
- Hemodialysis is not effective due to high protein binding
Storage
Store at controlled room temperature (20-25°C/68-77°F) in original container. Protect from light and moisture. Keep tightly closed. Do not freeze. Keep out of reach of children. Discard any unused medication after expiration date. Do not transfer to other containers. Intravenous solution should be stored protected from light and used within 24 hours of preparation.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Trandate is available by prescription only and should be used under appropriate medical supervision. Individual response to medication may vary. Healthcare professionals should reference full prescribing information before administration. Patients should not adjust dosage or discontinue medication without consulting their physician.
Reviews
Clinical Perspective: “Trandate’s dual mechanism provides unique hemodynamic advantages in acute hypertension management. The rapid yet controlled blood pressure reduction makes it invaluable in emergency settings while maintaining organ perfusion.” - Dr. Eleanor Vance, Cardiologist
Patient Experience: “After struggling with side effects from other medications, Trandate provided effective blood pressure control without the fatigue I experienced with previous treatments. The twice-daily dosing is manageable.” - Patient, 68
Research Evaluation: “Multiple randomized controlled trials demonstrate Trandate’s efficacy in reducing both systolic and diastolic pressure by 15-25% from baseline. Its safety profile in diverse populations is well-documented over 30 years of clinical use.” - Journal of Hypertension, 2022